Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.24 EUR | -0.32% | -6.20% | -9.49% |
Apr. 10 | Transgene: presents vaccine results at AACR | CF |
Mar. 28 | Transgene CFO Steps Down; Successor Assumes Office | MT |
Sales 2024 * | 39.8M 42.5M | Sales 2025 * | 49.8M 53.18M | Capitalization | 125M 134M |
---|---|---|---|---|---|
Net income 2024 * | -13M -13.88M | Net income 2025 * | -21M -22.43M | EV / Sales 2024 * | 3.55 x |
Net Debt 2024 * | 16.4M 17.51M | Net Debt 2025 * | 38.4M 41.01M | EV / Sales 2025 * | 3.28 x |
P/E ratio 2024 * |
-8.89
x | P/E ratio 2025 * |
-5.92
x | Employees | 141 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 34.45% |
Latest transcript on Transgene
1 day | -0.32% | ||
1 week | -6.20% | ||
Current month | +8.77% | ||
1 month | +9.35% | ||
3 months | -2.36% | ||
6 months | -12.68% | ||
Current year | -9.49% |
Managers | Title | Age | Since |
---|---|---|---|
Alessandro Riva
CEO | Chief Executive Officer | 63 | 22-03-30 |
Lucie Larguier
DFI | Director of Finance/CFO | - | 16-03-31 |
Maud Brandely
CTO | Chief Tech/Sci/R&D Officer | 70 | 16-03-16 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 74 | 13-06-18 | |
Alain Mérieux
BRD | Director/Board Member | 85 | 90-12-31 |
Director/Board Member | 63 | 04-12-06 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-30 | 1.24 | -0.32% | 18 662 |
24-04-29 | 1.244 | +2.81% | 18,787 |
24-04-26 | 1.21 | -5.47% | 74,243 |
24-04-25 | 1.28 | -4.90% | 50,816 |
24-04-24 | 1.346 | +1.82% | 12,204 |
Real-time Euronext Paris, April 30, 2024 at 11:35 am EDT
More quotesEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-9.49% | 134M | |
-3.14% | 102B | |
+1.66% | 96.29B | |
+2.13% | 22.18B | |
-15.81% | 21.2B | |
-9.21% | 18.31B | |
-39.98% | 17.38B | |
-15.56% | 16.36B | |
+5.01% | 13.97B | |
+32.42% | 12.17B |
- Stock Market
- Equities
- TNG Stock